263 related articles for article (PubMed ID: 22706847)
1. Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment.
Ito K; Stannard K; Gabutero E; Clark AM; Neo SY; Onturk S; Blanchard H; Ralph SJ
Cancer Metastasis Rev; 2012 Dec; 31(3-4):763-78. PubMed ID: 22706847
[TBL] [Abstract][Full Text] [Related]
2. Unraveling galectin-1 as a novel therapeutic target for cancer.
Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Neuzillet C; Albert S; Raymond E; Faivre S
Cancer Treat Rev; 2014 Mar; 40(2):307-19. PubMed ID: 23953240
[TBL] [Abstract][Full Text] [Related]
3. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.
Laderach DJ; Gentilini LD; Giribaldi L; Delgado VC; Nugnes L; Croci DO; Al Nakouzi N; Sacca P; Casas G; Mazza O; Shipp MA; Vazquez E; Chauchereau A; Kutok JL; Rodig SJ; Elola MT; Compagno D; Rabinovich GA
Cancer Res; 2013 Jan; 73(1):86-96. PubMed ID: 23108139
[TBL] [Abstract][Full Text] [Related]
4. Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease.
Dalotto-Moreno T; Croci DO; Cerliani JP; Martinez-Allo VC; Dergan-Dylon S; Méndez-Huergo SP; Stupirski JC; Mazal D; Osinaga E; Toscano MA; Sundblad V; Rabinovich GA; Salatino M
Cancer Res; 2013 Feb; 73(3):1107-17. PubMed ID: 23204230
[TBL] [Abstract][Full Text] [Related]
5. Galectin-1: a link between tumor hypoxia and tumor immune privilege.
Le QT; Shi G; Cao H; Nelson DW; Wang Y; Chen EY; Zhao S; Kong C; Richardson D; O'Byrne KJ; Giaccia AJ; Koong AC
J Clin Oncol; 2005 Dec; 23(35):8932-41. PubMed ID: 16219933
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth.
Liu XQ; Xiong MH; Shu XT; Tang RZ; Wang J
Mol Pharm; 2012 Oct; 9(10):2863-74. PubMed ID: 22924580
[TBL] [Abstract][Full Text] [Related]
7. On the role of galectin-3 in cancer apoptosis.
Nakahara S; Oka N; Raz A
Apoptosis; 2005 Mar; 10(2):267-75. PubMed ID: 15843888
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia inducible factor-1 mediates expression of galectin-1: the potential role in migration/invasion of colorectal cancer cells.
Zhao XY; Chen TT; Xia L; Guo M; Xu Y; Yue F; Jiang Y; Chen GQ; Zhao KW
Carcinogenesis; 2010 Aug; 31(8):1367-75. PubMed ID: 20525878
[TBL] [Abstract][Full Text] [Related]
9. Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress.
Ito K; Scott SA; Cutler S; Dong LF; Neuzil J; Blanchard H; Ralph SJ
Angiogenesis; 2011 Sep; 14(3):293-307. PubMed ID: 21523436
[TBL] [Abstract][Full Text] [Related]
10. Regulation of galectins by hypoxia and their relevance in angiogenesis: strategies and methods.
Salatino M; Croci DO; Laderach DJ; Compagno D; Gentilini L; Dalotto-Moreno T; Dergan-Dylon LS; Méndez-Huergo SP; Toscano MA; Cerliani JP; Rabinovich GA
Methods Mol Biol; 2015; 1207():293-304. PubMed ID: 25253148
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3--a jack-of-all-trades in cancer.
Newlaczyl AU; Yu LG
Cancer Lett; 2011 Dec; 313(2):123-8. PubMed ID: 21974805
[TBL] [Abstract][Full Text] [Related]
12. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk.
Orozco CA; Martinez-Bosch N; Guerrero PE; Vinaixa J; Dalotto-Moreno T; Iglesias M; Moreno M; Djurec M; Poirier F; Gabius HJ; Fernandez-Zapico ME; Hwang RF; Guerra C; Rabinovich GA; Navarro P
Proc Natl Acad Sci U S A; 2018 Apr; 115(16):E3769-E3778. PubMed ID: 29615514
[TBL] [Abstract][Full Text] [Related]
13. O-glycosylation regulates LNCaP prostate cancer cell susceptibility to apoptosis induced by galectin-1.
Valenzuela HF; Pace KE; Cabrera PV; White R; Porvari K; Kaija H; Vihko P; Baum LG
Cancer Res; 2007 Jul; 67(13):6155-62. PubMed ID: 17616672
[TBL] [Abstract][Full Text] [Related]
14. Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model.
Stannard KA; Collins PM; Ito K; Sullivan EM; Scott SA; Gabutero E; Darren Grice I; Low P; Nilsson UJ; Leffler H; Blanchard H; Ralph SJ
Cancer Lett; 2010 Dec; 299(2):95-110. PubMed ID: 20826047
[TBL] [Abstract][Full Text] [Related]
15. Galectin 3 as a guardian of the tumor microenvironment.
Ruvolo PP
Biochim Biophys Acta; 2016 Mar; 1863(3):427-437. PubMed ID: 26264495
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia control to normalize pathologic angiogenesis: potential role for endothelial precursor cells and miRNAs regulation.
Collet G; Skrzypek K; Grillon C; Matejuk A; El Hafni-Rahbi B; Lamerant-Fayel N; Kieda C
Vascul Pharmacol; 2012; 56(5-6):252-61. PubMed ID: 22446152
[TBL] [Abstract][Full Text] [Related]
17. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion.
Brahimi-Horn C; Pouysségur J
Bull Cancer; 2006 Aug; 93(8):E73-80. PubMed ID: 16935775
[TBL] [Abstract][Full Text] [Related]
18. Galectins in the Tumor Microenvironment: Focus on Galectin-1.
Martínez-Bosch N; Navarro P
Adv Exp Med Biol; 2020; 1259():17-38. PubMed ID: 32578169
[TBL] [Abstract][Full Text] [Related]
19. Altered N-glycosylation in CD45 and regulatory roles of altered N-glycosylation in galectin-1-induced growth inhibition in human diffuse large B cell lymphoma.
Suzuki O; Nozawa Y; Abe M
Oncol Rep; 2005 Jan; 13(1):109-14. PubMed ID: 15583810
[TBL] [Abstract][Full Text] [Related]
20. Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis.
Iurisci I; Cumashi A; Sherman AA; Tsvetkov YE; Tinari N; Piccolo E; D'Egidio M; Adamo V; Natoli C; Rabinovich GA; Iacobelli S; Nifantiev NE;
Anticancer Res; 2009 Jan; 29(1):403-10. PubMed ID: 19331179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
